



NEONATAL MEDICATION PROTOCOLS

SPIRONOLACTONE
Created by: NCCU
Date for review: Oct 2016

NCCU Clinical Guidelines
KEMH/PMH
Perth, Western Australia

DRUG:	SPIRONOLACTONE
PRESENTATION:	Oral Solution: 2.5 mg/mL
ACTION & INDICATION:	Potassium sparing diuretic. Valuable adjunct to therapy for congestive heart failure associated with hyperaldosteronism including chronic lung disease (BPD) and congenital heart disease.
DOSE:	0.75 to 1.5 mg/kg/dose 12 hourly.
ADMINISTRATION:	Oral: May be given at any time with regard to feeds.
ADVERSE EFFECTS:	Hyperkalaemia Hyponatraemia G.I. disturbances Rashes
COMMENTS:	Contraindicated in renal failure. Monitor serum electrolytes twice weekly. Response begins after 3 days of treatment and continues for 3 days after treatment stopped. Usually given in conjunction with other diuretics such as frusemide
REFERENCES:	Neonatal Pharmacopoeia 2 nd Ed Royal Women's Hospital Melbourne Neofax 2013
DATE:	October 2013